Article Text

Download PDFPDF
Original research
MSH3: a confirmed predisposing gene for adenomatous polyposis
  1. Marie-Charlotte Villy1,
  2. Julien Masliah-Planchon2,
  3. Anne Schnitzler2,
  4. Hélène Delhomelle2,
  5. Bruno Buecher2,
  6. Mathilde Filser2,
  7. Kevin Merchadou3,
  8. Lisa Golmard2,
  9. Samia Melaabi2,
  10. Sophie Vacher2,
  11. Maud Blanluet2,
  12. Voreak Suybeng2,
  13. Carole Corsini4,
  14. Marion Dhooge5,
  15. Nadim Hamzaoui6,
  16. Solenne Farelly5,
  17. Amal Ait Omar7,
  18. Robert Benamouzig7,
  19. Vincent Caumette8,
  20. Michel Bahuau8,
  21. Joël Cucherousset9,
  22. Yves Allory10,
  23. Dominique Stoppa-Lyonnet1,
  24. Ivan Bieche1,
  25. Chrystelle Colas2
  1. 1 Department of Genetics, Université Paris Cité, Institut Curie, Paris, France
  2. 2 Department of Genetics, PSL University, Institut Curie, Paris, France
  3. 3 Clinical Bioinformatics Unit, Institut Curie, Paris, France
  4. 4 Medical Genetics Department, Centre Hospitalier Regional Universitaire de Montpellier, Montpellier, France
  5. 5 Oncogenetic Unit, Department of Gastroenterology, AP-HP Centre-Université de Paris, Hopital Cochin, Paris, France
  6. 6 Department of Genetics, AP-HP Centre-Université de Paris, Hospital Cochin, Paris, France
  7. 7 Department of Gastroenterology, Hôpital Avicenne, Bobigny, France
  8. 8 Department of Genetics, Hôpitaux Universitaires Henri Mondor, Creteil, France
  9. 9 Department of Pathology, GHI Le Raincy-Montfermeil, Montfermeil, France
  10. 10 Department of Pathology, Université Paris-Saclay, Institut Curie, Paris, France
  1. Correspondence to Marie-Charlotte Villy, Department of Genetics, Institut Curie, Paris, 75005, France; marie-charlotte.villy{at}


Background The MSH3 gene is part of the DNA mismatch repair system, but has never been shown to be involved in Lynch syndrome. A first report of four patients from two families, bearing biallelic MSH3 germline variants, with a phenotype of attenuated colorectal adenomatous polyposis raised the question of its involvement in hereditary cancer predisposition. The patients’ tumours exhibited elevated microsatellite alterations at selected tetranucleotide repeats (EMAST), a hallmark of MSH3 deficiency.

Methods We report five new unrelated patients with MSH3-associated polyposis. We describe their personal and familial history and study the EMAST phenotype in various normal and tumour samples, which are relevant findings based on the rarity of this polyposis subtype so far.

Results All patients had attenuated colorectal adenomatous polyposis, with duodenal polyposis in two cases. Both women had breast carcinomas. EMAST phenotype was present at various levels in different samples of the five patients, confirming the MSH3 deficiency, with a gradient of instability in polyps depending on their degree of dysplasia. The negative EMAST phenotype ruled out the diagnosis of germline MSH3 deficiency for two patients: one homozygous for a benign variant and one with a monoallelic large deletion.

Conclusion This report lends further credence to biallelic MSH3 germline pathogenic variants being involved in colorectal and duodenal adenomatous polyposis. Large-scale studies may help clarify the tumour spectrum and associated risks. Ascertainment of EMAST may help with the interpretation of variants of unknown significance. We recommend adding MSH3 to dedicated diagnostic gene panels.

  • medical oncology
  • gastroenterology
  • genetic counseling
  • genetic predisposition to disease

Data availability statement

Data sharing not applicable as no datasets generated and/or analysed for this study.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data sharing not applicable as no datasets generated and/or analysed for this study.

View Full Text


  • Contributors Conceptualisation: M-CV and CC. Data curation: M-CV and CC. Formal Analysis: M-CV and JM-P. Investigation: AS and SV. Methodology: JM-P and LG. Project administration: DS-L, IB, JM-P and CC. Resources: CaC, MD, SF, AAO, RB, VC, MF and MBa. Software: SM, MBl, VS, KM and NH. Supervision: DS-L, IB and CC. Validation: JC and YA. Visualisation: M-CV, HD and BB. Writing—original draft: M-CV and CC. Writing—review and editing: all authors. All authors revised the manuscript critically and approved the version of the manuscript to be published. Guarantor: CC.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.